Kura Oncology, Inc. (NASDAQ:KURA) Given Average Rating of “Moderate Buy” by Analysts

Shares of Kura Oncology, Inc. (NASDAQ:KURA) have received a consensus recommendation of “Moderate Buy” from the thirteen brokerages that are currently covering the stock, Marketbeat.com reports. Three equities research analysts have rated the stock with a hold rating, eight have given a buy rating and two have assigned a strong buy rating to the company. The average 1 year price target among analysts that have updated their coverage on the stock in the last year is $23.89.

Several equities research analysts recently weighed in on the stock. BTIG Research downgraded shares of Kura Oncology from a “buy” rating to a “neutral” rating in a report on Thursday, February 6th. Wedbush reaffirmed an “outperform” rating and issued a $36.00 price target on shares of Kura Oncology in a research note on Tuesday, April 8th. Barclays lowered their price objective on shares of Kura Oncology from $32.00 to $11.00 and set an “overweight” rating on the stock in a research note on Friday. UBS Group cut their target price on Kura Oncology from $27.00 to $14.00 and set a “buy” rating for the company in a research report on Thursday, March 6th. Finally, JMP Securities reiterated a “market outperform” rating and set a $28.00 price target on shares of Kura Oncology in a research report on Tuesday, April 29th.

Institutional Investors Weigh In On Kura Oncology

Several hedge funds have recently modified their holdings of KURA. Virtus ETF Advisers LLC raised its holdings in Kura Oncology by 71.6% during the 4th quarter. Virtus ETF Advisers LLC now owns 7,336 shares of the company’s stock worth $64,000 after buying an additional 3,061 shares during the period. Harbor Advisors LLC purchased a new position in shares of Kura Oncology in the fourth quarter worth approximately $87,000. Pallas Capital Advisors LLC acquired a new stake in shares of Kura Oncology during the first quarter valued at approximately $66,000. E Fund Management Co. Ltd. purchased a new stake in shares of Kura Oncology in the 4th quarter valued at approximately $90,000. Finally, Corton Capital Inc. purchased a new stake in shares of Kura Oncology in the 4th quarter valued at approximately $99,000.

Kura Oncology Price Performance

Shares of NASDAQ:KURA opened at $6.47 on Friday. The firm’s 50 day moving average is $6.73 and its two-hundred day moving average is $9.58. The firm has a market capitalization of $522.63 million, a P/E ratio of -2.74 and a beta of 0.50. The company has a current ratio of 11.47, a quick ratio of 11.47 and a debt-to-equity ratio of 0.02. Kura Oncology has a 52 week low of $5.41 and a 52 week high of $23.48.

Kura Oncology (NASDAQ:KURA) last posted its earnings results on Thursday, May 1st. The company reported ($0.66) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.15). The company had revenue of $14.11 million during the quarter, compared to analysts’ expectations of $39.08 million. Analysts anticipate that Kura Oncology will post -2.44 earnings per share for the current year.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.